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Abstract
Using a unique resource of samples from a controlled humanmalaria infection (CHMI)
study, we identified a novel population of CD4+ T cells whose frequency in the peripheral
blood was inversely correlatedwith parasite burden following P. falciparum infection. These
CD4+ T cells expressed the multifunctional ectoenzymeCD38 and had unique features that
distinguished them from other CD4+ T cells. Specifically, their phenotype was associated
with proliferation, activation and cytotoxic potential as well as significantly impaired produc-
tion of IFN-γ and other cytokines and reduced basal levels of activated STAT1. A CD38+
CD4+ T cell population with similar features was identified in healthy uninfected individuals,
at lower frequency. CD38+ CD4+ T cells could be generated in vitro fromCD38- CD4+ T
cells after antigenic or mitogenic stimulation. This is the first report of a population of CD38+
CD4+ T cells with a cytotoxic phenotype and markedly impaired IFN-γ capacity in humans.
The expansion of this CD38+ CD4+ T population following infection and its significant asso-
ciation with reduced blood-stage parasite burden is consistent with an important functional
role for these cells in protective immunity to malaria in humans. Their ubiquitous presence
in humans suggests that they may have a broad role in host-pathogendefense.
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Author Summary
Malaria is one of the three most deadly infectious diseaseworldwide, together with tubercu-
losis and HIV. The exact mechanisms underlying effective immunity to malaria remain
largely unknown and there is no reliable immune correlate of protection. Here, we take
advantage of a unique experimental human infectionmodel to define the immune response
to primary exposure of blood-stagemalaria parasites in naïve healthy volunteers at the
molecular level. We report that Plasmodium parasite levels were inversely correlated to the
expansion of a specific subset of CD4+ T cells expressing the activation moleculeCD38
and a very unusual phenotype. Although the expansion of CD38+ CD4+ T cells has been
described in several viral and bacterial infections, we show for the first time that these
cells are associated with a ‘naive-like’ effector phenotype, higher cytolytic potential and a
strongly impaired ability to produce IFN-γ and other cytokines. Importantly, this subset of
CD38+ CD4+ T cells could be also identified in all healthy volunteers prior to infection, sug-
gesting that these core characteristics of circulating CD38+ CD4+ T cells are independent of
active infection and may play an important role in the immune control of other pathogens.
Introduction
Malaria is associated with complex multi-factorial immune responses, due in part to the multi-
stage life cycle of the Plasmodium spp. parasite which is targeted by multiple arms of the
immune system, and the existence of elaborate host-pathogen interactions and evasionmecha-
nisms [1]. The effector cells and immune mediators contributing to protection against the spo-
rozoite, liver, and blood-stages of malaria have been the subject of intense investigation over
many years [2–4], but the specificmolecularmechanisms and critical effector cells that mediate
control of parasite burden remain largely unknown [1,3,5].
CD4+ T cells have been implicated in the control of blood-stage parasitemia in numerous ani-
mal models [6]; and in humans an associationwith parasite control has been demonstrated in
studies utilizingCHMI [7,8]. An important effector function of CD4+ T cells is the production of
various pro- and anti-inflammatory cytokines including IFN-γ, IL-2, IL-4, IL-10, IL-17 and TNF
[9]. In blood-stagemalaria, IFN-γ has been implicated as the key cytokine driving effective
immune responses [10], and circumstantial evidence associates CD4+ T cells producing IFN-γ
with protection against P. falciparum blood-stage infection in humans [7,8]. CD4+ T cells express-
ing the degranulationmarker CD107a have been identified in circulating PBMCs from subjects
protected by immunization with P. falciparum sporozoites under the cover of chloroquine chemo-
prophylaxis following in vitro stimulation with P. falciparum–infected red blood cells [11]. Cyto-
lytic CD4+ T cells have also been describedas potent immune effectors in protection against
many viral infections, including CMV, Epstein-Barr Virus, Influenza and HIV [12–14].
In humans, recently activated T cells are typically identified ex vivo via the upregulation of
cell surface glycoproteins such as CD69 or CD38 [15]. CD69 is one of the earliest molecules
detected on the T cell surface following TCR engagement, and CD69 mediated signaling results
in a range of cellular responses including proliferation [16]. CD38 is expressed on the surface
of immature but not mature hematopoietic cells, and is also re-expressed by many immune
cells (including CD4+ T cells) after activation [17,18]. Circulating T cells expressing CD38 dur-
ing infection have been associated with a recently activated effector phenotype [19,20]; and
antigen-specificCD4+ T cells have been shown to express high levels of CD38 and produce
IFN-γ in the acute phase of several viral infections including EBV [21], HIV [22] and Influenza
[23]. CD38 is a multifunctionalmolecule that acts as an ectoenzyme to catalyze the conversion
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of NAD+ to the second-messenger cyclic-ADB-ribose (cADPR) and is considered the major
regulator of intracellular and extracellular NAD+ levels [24]. The purpose of CD38 signaling in
T cell immunity is not fully elucidated, although there is strong evidence that the products of
CD38 enzymatic activity (principally cADPR) enhance intracellular calciummobilization
which is required for a multitude of cell functions including lymphocyte proliferation [25] and
lymphocyte migration [26,27]. Signaling through CD38 has also been reported to promote the
activation and cytotoxic function of human NK cells [28,29].
Experimental infectionmodels provide an excellent opportunity to investigate the mecha-
nisms underlying the induction of immunity following primary exposure of the human
immune system to target pathogens. Here, we utilized a model of controlled human malaria
infection (CHMI) of naive healthy volunteers [30–32] to explore the mechanisms underlying
the induction of T-cell-associated immunity in blood-stagemalaria.We show that the levels of
parasite burden following experimentalP. falciparum blood-stage infection inversely correlated
with the expansion of a specific subset of CD4+ T cells expressing CD38 and characterized by
high cytotoxic potential but impaired cytokine production. These cells were also present at
lower frequency in healthy uninfected individuals, and could be generated in vitro from CD38-
CD4+ T cells after antigenic or mitogenic stimulation.
Results
Control of parasite burden following first-exposure to P. falciparum
correlateswith the expansion of CD38+ CD4+ T cells
To determine whether significant changes could be detected in the phenotype of circulating
lymphocytes following infection, the frequencies of T cells and B cells expressing the activation
markers CD69 or CD38 were measured prior to and seven days post-infectionwith P. falcipa-
rum. In all volunteers, infection led to a significant increase in the frequency and absolute num-
bers of CD69+ T cells and B cells (Fig 1A and S1 Fig). There was a higher frequency of CD38+
CD4+ T cells but not CD38+ CD8+ T cells or B cells (Fig 1A), and absolute numbers of CD38+
CD4+ T cells and B cells also increased in the peripheral blood during infection (S1 Fig). In the
same volunteers, measurement of the level of parasitemia by qPCR over the first seven days of
infection revealed a variation in parasite burden between individuals. Thus, we compared the
changes in frequency of CD69+ and CD38+ T cells and B cells during infectionwith parasite
burden, to determine if a certain cell type or phenotype was associated with parasite control.
Univariate regression analysis revealed no significant association between the changes in the
frequency of CD69+ T cells or B cells and the parasite burden during infection (Fig 1B, top
panel). However, an inverse correlation between the frequency of CD38+ T cells and B cells
and parasite burden during infection was apparent (Fig 1B, bottom panel). Multivariate regres-
sion analysis with forward selection revealed that the fold change in the frequency of CD38+ in
CD4+ T cells was the only variable significantly negatively associated with parasite burden
(p = 7.5E-05). Thus, in malaria-naive volunteers, reduced parasite burden during primary
blood-stageP. falciparum infectionwas associated with the expansion of a specific subset of
CD4+ T cells expressing the activation marker CD38.
CD38+ CD4+ T cells in P. falciparum infected individuals have a ‘naïve-
like’ effector phenotype associated with proliferation, activation and
cytolytic potential
In order to further delineate the differentiation state of CD38+ CD4+ T cells, we measured their
surface expression of the naïve marker CD45RA. Similarly to previous reports [33], we found
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Fig 1. Changes in the frequency of CD69+ andCD38+ T cells and B cells circulatingduringP. falciparumblood-
stage infectionand their associationwith parasite burden. Peripheral blood was collected prior to and seven days
post-infection of malaria-naïve individualswith ~ 1800 pRBCs and the frequency of CD69+ or CD38+ T cells and B cells
determined by flow cytometry. Parasite burden was calculated as the Area Under the Curve from blood parasite levels
measured by qPCR from day 0 to day 7 post-infection. (A) Frequency of CD69+ or CD38+ T cells and B cells circulating
pre- and post-infection. (B)Univariate regression analysis of the changes in frequency of CD69+ or CD38+ T cells and B
cells circulating during infection and parasite burden. Statistical differences between cell frequencies pre- and post-
infection were determinedusing the non-parametricWilcoxon test; box and whisker plots indicatemedian, interquartile
range andmin-max. Univariate regression analysis was performed with R, and p values adjusted for multiple
comparisons using the Bonferroni method.Graphs show combined data from 22 volunteers from five independent
cohorts.**, p < 0.01; ***, p < 0.001.
doi:10.1371/journal.ppat.1005839.g001
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that a greater proportion of CD38+ CD4+ T cells expressed CD45RA in comparison to CD38-
CD4+ T cells both prior to, and at peak infection (Fig 2A and 2B). Furthermore, there was an
increased in the frequency of CD45RA+ cells at 7 days post infection compared to prior to
infection in CD38+ but not in CD38- CD4+ T cells (Fig 2C).
Effector T cell populations expanding in response to infection or immunization have been
shown to express high levels of CD38 and the proliferation marker Ki67 but low levels of the
anti-apoptotic molecule Bcl2 [19]. Accordingly, we measured the expression of Ki67 and Bcl2
by flow cytometrywithin CD38+ and CD38- CD4+ T cells circulating in the healthy volunteers
prior to infection, as well as at peak of infection seven days after inoculation. The expression of
Ki67 was significantly increased in CD38+ CD4+ T cells compared to CD38- CD4+ T cells prior
to and during infection (p< 0.0001, Fig 2D and 2E). Additionally, the frequency of Ki67+ cells
decreased at 7 days post infection compared to prior to infection in CD38+ but not in CD38-
CD4+ T cells (Fig 2F). Conversely, the expression of the anti-apoptotic marker Bcl2 was signifi-
cantly reduced in CD38+ CD4+ T cells compared to CD38- CD4+ T cells both prior to and at
peak infection (p = 0.002, Fig 2G and 2H). In both cell subsets, there was an overall decrease in
Bcl2 expression at 7 days post infection compared to prior to infection, but to a greater extent
for CD38+ CD4+ T cells (Fig 2I). Thus, CD38+ CD4+ T cells were associated with a ‘naïve-like’
effector T cell phenotype (CD45RA+Ki67+Bcl2low), and the proportion of cells expressing each
marker was significantly affected upon infectionwithin this cell subset.
As CD38 upregulation has been observed following TCR-signaling of CD4+ T cells [21–23],
we reasoned that CD38+ CD4+ T cells might have increased activation following TCR in vitro
stimulation compared to CD38- CD4+ T cells. We assessed the level of activation of the FACS-
purifiedCD38+ and CD38- CD4+ T cells via TCR stimulation by measuring their capacity to
upregulate CD69 expression after short in vitro stimulation with anti-CD3. Prior to infection,
there was no significant increase in CD69 expression following TCR stimulation for both
CD38+ and CD38- CD4+ T cells (Fig 2J and 2K), although the basal expression of CD69 was
higher on CD38+ CD4+ T cells. Post-infection, while both cell types significantly upregulated
CD69 expression following TCR stimulation (Fig 2J and 2K), fold change was significantly
higher for CD38- CD4+ T cells compared to CD38+ CD4+ T cells (average fold change of 13.7
and 1.4 for CD38- CD4+ T cells and CD38+ CD4+ T cells, respectively, p = 0.016). However, the
higher basal expression of CD69 for CD38+ CD4+ T cells was maintained. These results suggest
that P. falciparum blood-stage infection of humans led to an increased level of activation fol-
lowing TCR stimulation in both CD38+ and CD38- CD4+ cell subsets, albeit to a greater extent
for CD38- CD4+ T cells. Furthermore, CD38+ CD4+ T cells constitutively express higher levels
of CD69 compared to CD38- CD4+ T cells.
A recent report associated CD4+ T cells expressing the degranulationmarker CD107a with
protection against malaria in sporozoite-immunized volunteers [11], and CD38 has been
implicated in the cytotoxic activity of NK cells [28,29]. Thus, we examined the cytolytic
potential of CD38+ CD4+ T cells by measuring their intracellular expression of perforin and
granzyme B by flow cytometry both prior to and at peak infection. The frequency of cells
expressing perforin or granzyme B was significantly greater in CD38+ CD4+ T cells than in
CD38- CD4+ T cells prior to and post infection (p = 0.001 and p = 0.011 prior to infection, and
p = 0.012 and p = 0.017 at peak infection for perforin and granzyme B, respectively, Fig 3A and
3B). Additionally, the CD38+ CD4+ T cells contained a higher proportion of cells co-expressing
perforin and granzyme B (p = 0.001 and p = 0.006 prior to and at peak infection, respectively,
(Fig 3B). The proportion of cells expressing granzyme B and/or perforin within either CD38+
or CD38- CD4+ T cell subsets did not change markedly during the course of infection (Fig 3C).
Eomesodermin (Eomes), a key transcription factor associated with the cytolytic activity of
CD4+ T cells [34,35] was expressed at similar levels by CD38+ and CD38- CD4+ T cells prior to
Cytotoxic CD38+ CD4+ T Cells with Impaired IFN-γ
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Fig 2. CD38+ CD4+ T cells have a ‘naïve-like’ effector phenotype associated with proliferation and recent activation. (A)Representative
staining of one volunteer and (B-C) the frequencies of CD45RA+ cells in CD38- (black) or CD38+ (red)CD4+ T cells determined by flow cytometry in
volunteers prior to and seven days post infection. (D)Representative staining of one volunteer and (E-F) the frequencies of Ki67+ cells in CD38-
(black) or CD38+ (red) CD4+ T cells determined by flow cytometry in volunteers prior to and seven days post infection. (G)Representative staining of
one volunteer and (H-I) the average expression of Bcl2 in CD38- (black) or CD38+ (red)CD4+ T cells determined by flow cytometry in volunteers prior
to and seven days post infection. (J)Representative staining of one volunteer and (K) the frequencies of CD69+ cells measured by flow cytometry in
CD38- (black) or CD38+ (red) CD4+ T cells freshly isolated from volunteers prior to and seven days post infection after brief stimulationwith plate-
bound anti-human CD3 antibody. Graphs show combined data from (A-F) 22 volunteers from five independent cohorts, (G-I) 13 volunteers from two
independent cohorts, (J-K) seven volunteers from one cohort.Statistical differences betweenCD38- and CD38+ CD4+ T cells or between pre- and
post-infectionwere determined using the non-parametricWilcoxon test; box and whisker plots indicatemedian, interquartile range andmin-max;
*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001 ns, p > 0.05.
doi:10.1371/journal.ppat.1005839.g002
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Fig 3. CD38+ CD4+ T cells have a phenotypeassociatedwith cytotoxic potential. (A) Representative staining in one volunteer and
(B-C) frequencies of CD38- (black) or CD38+ (red)CD4+ T cells expressing perforin+, granzyme B+ (GrzB) or perforin+/granzymeB+
determined by flow cytometry in volunteers prior to and seven days post infection. (D)Eomes gene expression measured by RT-qPCR in
CD38- (black) or CD38+ (red)CD4+ T cells isolated from volunteers prior to and seven days post infection. Graphs show combined data
from (A-C) 13 volunteers from two independent cohorts, (D) seven (pre) and three (post) volunteers from one cohort. Statistical
differences betweenCD38- and CD38+ CD4+ T cells or between pre- and post-infection were determined using the non-parametric
Wilcoxon test; box and whisker plots indicatemedian, interquartile range andmin-max;*, p < 0.05; **, p < 0.01; ***, p < 0.001;
****, p < 0.0001.
doi:10.1371/journal.ppat.1005839.g003
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infection.However, a trend for an increase in Eomes expression in CD38+ CD4+ T cells follow-
ing infectionwas observed (Fig 3D). Taken together, these results suggest that the CD38+
CD4+ T cell subset that expands during P. falciparum infection defines an effector population
with cytolytic potential.
CD38+ CD4+ T cells are a subset of conventional TCR-αβCD4+ T cells
We next confirmed that the circulating CD38+ CD4+ T cells belong to a conventional CD4+ T
cell subset and not to another immune cell type known to have a strong cytotoxic activity, such
as NK cells or NKT cells. The CD38+ CD4+ T cells were all positive for CD3 expression (99.5
±0.5%, marker for T cell lineage) and mainly positive for TCR-αβ expression (83.4±5.8%,
marker for αβ T cells) but were negative for TCR-γδ expression (0.16±0.1%,marker for γδ T
cells [36]), TCR-Vα24Jα18 expression (0.25±0.2%,marker for NK T cells [37]), CD25 expres-
sion (0.93±0.8%,marker for regulatory T cells [38]), as well as CD56 and Nkp46 expression
(0.35±0.2% and 0.36±0.2%, respectively, markers for NK cells [39]) (Fig 4A and 4B). Thus, cir-
culating CD38+ CD4+ T cells represent a subset of conventional TCR-αβ CD4+ T cells.
T follicular helper (Tfh) cells are conventional CD4+ T cells responsible for the generation
of long-lived and high affinity antibody responses [40]. Activation and expansion of a specific
subset of Tfh cells was observed in the peripheral blood of children experiencing acute malaria
infection [41]. Both prior to and at peak infection, the frequency of CD45RA-CXCR5+ Tfh cells
was significantly higher amongst CD38- CD4+ T cells compared to CD38+ CD4+ T cells (Fig
4C and 4D), and Tfh cells represented a small fraction of the total CD38+ CD4+ T cell popula-
tion (average of 5.6% and 5% of total CD38+ CD4+ T cells prior to, and at peak infection,
respectively, Fig 4C and 4D). Thus, circulating CD38+ CD4+ T cells that expand during infec-
tion do not represent a specific subset of Tfh cells.
CD38+ CD4+ T cells are poor producers of IFN-γ
IFN-γ is considered the key effector cytokine in malaria [10], and cytolytic CD4+ T cells have
been shown to produce high levels of IFN-γ upon in vitro stimulation [42]. To compare the
ability of CD38+ and CD38- CD4+ T cells to produce IFN-γ, we assessed the frequency of IFN-
γ positive cells induced by mitogenic stimulation in CD38+ and CD38- CD4+ T cell populations
collected prior to and at peak infection seven days later. Unexpectedly, IFN-γ production was
significantly impaired in the CD38+ CD4+ T cell subset both prior to and during infection
(p = 0.031 and p = 0.031) (Fig 5A and 5B). For both cell subsets, infection did not trigger
changes in their capacity to produce IFN-γ in response to stimulation (Fig 5C). The
impairment of IFN-γ production in CD38+ CD4+ T cells is apparently controlled at the level of
gene expression as IFN-γmRNA was significantly reduced in mitogen-stimulated CD38+
CD4+ T cells taken from healthy uninfected volunteers when compared to their CD38- CD4+ T
cells (Fig 5D), and was also apparent for several other cytokines including IL-2, TNF, IL-4,
IL-10 and IL-17 (Fig 5E).
Since the CD38+ CD4+ T cell population displayed a phenotype associated with recent acti-
vation combined with a marked inability to produce cytokines, we next confirmed that the
CD38+ CD4+ T cells were not undergoing apoptosis through an activation-induced cell death
mechanism [43]. CD38+ CD4+ T cells stained negatively for the apoptotic marker Annexin-V
and the viability stain propidium iodide (Pi) prior to infection (98.4±0.5%Annexin-V-, 99.8
±0.5% Pi-) and during infection (98.8±0.8%Annexin-V-, 99.8±0.2% Pi-). Thus, the CD38+
CD4+ T cell population contains viable cells that are not undergoing apoptosis.
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Fig 4. CD38+ CD4+ T cells are a subset of conventional TCR-αβCD4+ T cells.Peripheral blood was collected prior to and seven days post-
infection and the lineage phenotype of CD38+ CD4+ T cells determined by flow cytometry. (A)Representative staining of CD3, CD4, TCR-αβ, TCR-γδ,
TCR-Vα24Jα18, CD25, CD56 and Nkp46 within CD38+ CD4+ T cells (red) or total lymphocytes (grey) from one volunteer. (B)Mean frequency of CD3,
TCR-αβ, TCR-γδ, TCR-Vα24Jα18, CD25, CD56 and Nkp46 positive cells within CD38+ CD4+ T cells circulating prior to and seven days post-infection.
Graphs show combined data from seven volunteers from one cohort; error bars indicate SD. (C) Concatenated plot representing the frequency of
CXCR5+CD45RA- cells within CD38+ CD4+ T cells or CD38- CD4+ T cells from6 volunteers at seven days post infection. (D) Mean frequency of
CXCR5+CD45RA- cells within CD38+ CD4+ T cells (red) or CD38- CD4+ T cells (black) prior to and seven days post infection. Graphs show combined
data from eight (pre) and six (post) volunteers from one cohort.Statistical differences betweenCD38- and CD38+ CD4+ T cells were determined using
the non-parametricWilcoxon test; box and whisker plots indicatemedian, interquartile range andmin-max; *, p < 0.05; **, p < 0.01.
doi:10.1371/journal.ppat.1005839.g004
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Reduced levels of activated pSTAT1 in CD38+ CD4+ T cells
To determine whether the impaired ability of CD38+ CD4+ T cells to produce IFN-γ and other
cytokines was due to a specific defect in cytokine-associated signaling pathways, we investi-
gated the level of phosphorylated STATs within CD38+ CD4+ T cells using Phosphoflow [44].
STAT1 is mainly phosphorylated through stimulation with type I or type II IFNs [45], and a
critical role for STAT4 activation by type I IFNs in the IFN-γ response has been reported [46].
Consistent with this, CD38+ CD4+ T cells displayed significantly reduced levels of both
pSTAT1 and pSTAT4 compared to CD38- CD4+ T cells (p = 0.016 and p = 0.031 prior to infec-
tion, and p = 0.0002 and p = 0.0002 post-infection for pSTAT1 and pSTAT4, respectively; Fig
6A and 6B). Unexpectedly, since STAT5 mediates IL-2 signaling in T cells [47] and we found
that IL-2 production by CD38+ CD4+ T cells was significantly reduced compared to CD38-
CD4+ T cells (Fig 5E), the levels of pSTAT5 were similar betweenCD38+ and CD38- CD4+ T
cells (Fig 6A and 6B), suggesting that both cells subsets retain similar capacity to respond to IL-
2. Upon infection, the levels of pSTAT1 and pSTAT4 within both CD38+ and CD38- CD4+ T
cells decreased (Fig 6C), while the expression of pSTAT5 was significantly decreased in the
CD38+ CD4+ T cell subset only (Fig 6C).
Fig 5. CD38+ CD4+ T cells are poor producers of IFN-γ following in vitro stimulation. (A-C)Peripheral blood was collected prior to and seven
days post-infection and CD38- (black) and CD38+ (red) CD4+ T cells isolated using cell sorting. Intracellular IFN-γ production after briefmitogenic
stimulationwith PMA and Ionomycin was measured at the protein level using flow cytometry. (D-E)Peripheral blood was collected from healthy
uninfected volunteers and (D) IFN-γ and (E) IL-2, TNF, IL-4, IL-10 and IL-17 gene expression after briefmitogenic stimulationwith PMA and
Ionomycin was measured by RT-qPCR. Gene expression was normalized to reference gene RPL13A. Graphs show combined data from (A-C) four to
seven volunteers from one cohort and (D-E) 12 healthy volunteers; statistical differences betweenCD38+ and CD38- CD4+ T cells and between prior
to and seven days post infection were determinedusing the non-parametricWilcoxon test; box and whisker plots indicatemedian, interquartile range
andmin-max;*, p < 0.05, **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.
doi:10.1371/journal.ppat.1005839.g005
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Differences in the basal levels of pSTAT1 between the two CD4+ T cell subsets were not due
to differences in total STAT1 protein as there was no apparent difference in the levels of intra-
cellular STAT1 betweenCD38- and CD38+ CD4+ T cells (Fig 6D).
In order to determine whether the observeddifferences in basal levels of pSTAT1 were due
to variation in cytokine responsiveness, we assessed the phosphorylation levels of STAT1 in
CD38+ and CD38- CD4+ T cells isolated from healthy uninfected volunteers following in vitro
exposure to IFN-γ or IFN-α. In both cell subsets, a 15 min exposure to IFN-γ induced a small
but insignificant increase in phosphorylation of STAT1 (Fig 6E). However, IFN-α exposure
induced significant phosphorylation of STAT1 (both p = 0.0313, with non-parametric Wil-
coxon test) and brought the levels of pSTAT1 to similar levels in the CD38- and CD38+ subsets
(Fig 6E), indicating a similar responsiveness to IFN-α and ability to phosphorylate STAT1 and
excluding a specific defect in the ability of CD38+ T cells to phosphorylate STAT1.
Fig 6. CD38+ CD4+ T cells have a different STAT phosphorylation profile compared to CD38- CD4+ T cells. (A)
Representative staining of one volunteer and (B-C) the expression levels of pSTAT1, pSTAT4 and pSTAT5 in CD38-
(black) or CD38+ (red) CD4+ T cells measured ex vivo by phospho-epitope specific flow cytometry in volunteers prior to
and seven days post infection. (D) The expression level of total STAT1 protein in CD38- (black) or CD38+ (red) CD4+ T
cells from healthy uninfected volunteersmeasured by flow cytometry. (E) The expression level of pSTAT1 in CD38-
(black) or CD38+ (red) CD4+ T cells from healthy uninfected volunteers measuredby phospho-epitope specific flow
cytometry ex vivo or after 15 mins stimulation with 100 ng/mL human recombinant IFN-γ or IFN-αmeasured by phospho-
epitope specific flow cytometry. Differences between CD38- and CD38+ CD4+ T cells and between prior to and seven
days post infection were determinedwith the non-parametricWilcoxon test; box and whisker plots indicate median,
interquartilerange andmin-max.Graphs show combined data from (A-C) seven volunteers from one cohort (pre) and 13
volunteers from two separate cohorts (post), (D-E) six healthy controls. *, p < 0.05; ***, p < 0.001 ns, p > 0.05.
doi:10.1371/journal.ppat.1005839.g006
Cytotoxic CD38+ CD4+ T Cells with Impaired IFN-γ
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CD38- CD4+ T cells have the ability to differentiate into CD38+ CD4+ T
cells upon in vitro stimulation
Finally, we investigated the cell subset precursor of the CD38+ CD4+ T cells that expanded in
vivo upon infection. Since there was no change in absolute numbers of CD4+ T cells in the
peripheral blood of infected volunteers during infection (S2 Fig), we hypothesized that the
increase in the frequency and absolute numbers of CD38+ CD4+ T cells circulating during
infectionmight result from the differentiation of naive CD4+ T cells into activated CD38+
CD4+ T cells, rather than from the proliferation of pre-existing CD38+ CD4+ T cells. To test
this, isolated CD38- CD4+ T cells from healthy uninfected volunteers were stimulated in vitro
for 7 days, and then assayed for expression of CD38 by flow cytometry. Consistent with our
hypothesis, stimulation with both parasite antigen and mitogen resulted in a significant upre-
gulation of CD38 (Fig 7A and 7B). Similar to the CD38+ CD4+ T cells circulating in vivo in the
P. falciparum experimental infectionmodel, this in vitro generated CD38+ CD4+ T cell popula-
tion showed a phenotype associated with recent activation (Fig 7C and 7D) and cytotoxic
potential at both protein (Fig 7E and 7F) and mRNA levels (Fig 7G). Unlike endogenous
CD38+ CD4+ T cells, these in vitro generated CD38+ CD4+ T cells had similar capacity to pro-
duce IFN-γ (Fig 7H) as well as other cytokines (S3 Fig) upon in vitro stimulation.
Discussion
Herein, we identify a novel population of CD38+ CD4+ T cells displaying cytolytic potential
and a phenotype associated with proliferation and activation. Increased frequency of CD38+
CD4+ T cells in the peripheral blood of human volunteers inversely correlated with parasite
burden in an experimental blood-stagemalaria infectionmodel. Importantly, these CD38+
CD4+ T cells had a significantly reduced ability to produce IFN-γ and several other cytokines,
and contained reduced basal levels of phosphorylated STAT1, compared to CD38- CD4+ T
cells. This CD38+ CD4+ T cell population was also present at low frequency in all healthy unin-
fected individuals we tested. CD38+ CD4+ T cells with cytolytic potential could be generated in
vitro from CD38- CD4+ T cells following exposure to antigen or mitogen but did not display
impaired cytokine expression.
The CD38+ CD4+ T cells we described in this study have features of both naïve and effector
T cells, but are distinguished by their strongly impaired cytokine function. These results are in
concordance with the previous study of Plebanski et al. describing a specific subset of circulat-
ing CD4+ T cells expressing CD38 and CD45RA but with reduced proliferation and Th1 cyto-
kine production upon TCR stimulation [33]. In our study, the CD38+ CD4+ T cells circulating
during infection displayed a phenotype associated with recent activation and cytotoxic poten-
tial, suggesting that this cell population may be a subset of cytolytic CD4+ T cells. We are aware
of one early report of cytotoxic CD4+ T cell generation in a human volunteer following experi-
mental immunization irradiated P. falciparum sporozoites [48] and protection from sporozoite
infection conferred by adoptive transfer of cytolytic CD4+ T cell clones in a rodent model [49].
Both of those examples utilized the liver-stage of the parasite where the host cells include
MHC-II expressing Kupffer cells and hepatocytes and there is solid evidence that cytolytic
CD4+ T cells can induce death in target cells throughMHC-II dependent mechanisms, thereby
contributing to protection against pathogens with a tropism for MHC-II expressing cells
[9,12]. However, since red blood cells lack MHC-II molecules, so the mechanism by which
CD38+ CD4+ T cells could exert their cytotoxic function in blood-stagemalaria remains to be
elucidated. One possibility is that the cells might be operating through a MHC-independent
mechanism, as observed in NK cells [50]. Alternatively, the cytolytic CD38+ CD4+ T cells
might be responsible for MHC-II dependent killing of recently activated antigen presenting
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cells (APCs) in order to prevent the development of exacerbated pro-inflammatory responses.
Indeed, it has been demonstrated that CD4+ T cells can mediate both cytotoxic and suppressor
functions in vitro [51] and that cytolytic CD4+ T cells can directly induce apoptosis of activated
APCs [52]. Thus, we speculate that the function of our novel population of CD38+ CD4+ T
cells during infectionmight be to control and restrain the immune response, rather than to
promote it.
Fig 7. CD38- CD4+ T cells can differentiate intoCD38+ CD4+ T cells upon in vitro stimulation. (A)Representative staining of
one volunteer and (B) the frequency of CD38+ cells measured by flow cytometry in CD38- CD4+ T cells isolated from healthy
volunteers and in vitro stimulatedwith P. falciparumparasitized red blood cells extract (pRBC) at 106 pRBC/mLor PHA at 5 μg/mL
for seven days. (C-H)CD38- CD4+ T cells were isolated from healthy volunteers, in vitro stimulated for seven days with 5 μg/mLPHA
and sorted into CD38- and CD38+ CD4+ T cells for flow cytometry or gene expression analysis. (C)Representative staining of one
volunteer and (D) the frequencies of CD69+ cells measured by flow cytometry in CD38- (black) or CD38+ (red) CD4+ T cells. (E)
Representative staining of one volunteer and (F) the frequencies of Perforin+ and GranzymeB+ cells determined by flow cytometry
in CD38- (black) or CD38+ (red)CD4+ T cells. (G)Gene expression of Perforin and GranzymeBmeasuredby RT-qPCR in CD38-
(black) or CD38+ (red) CD4+ T cells. (H) IFN-γ gene expression measured by RT-qPCR after PMA and Ionomycin stimulation of
CD38- (black) or CD38+ (red) CD4+ T cells. Gene expression was normalized to reference gene RPL13A. Graphs show combined
data from (A-B) six and (C-H) four healthy volunteers. Differences between culture conditions were determined using the non-
parametricWilcoxon test; box and whisker plots indicatemedian, interquartile range andmin-max;*, p<0.05 ns, p > 0.05.
doi:10.1371/journal.ppat.1005839.g007
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Unexpectedly, we found that these CD38+ CD4+ T cells are very poor producers of IFN-γ in
response to mitogenic stimulation, compared to CD38- CD4+ T cells. This result was surprising
because IFN-γ has been implicated as the main effector cytokine produced by CD4+ T cells and
contributing to protective immunity to blood-stagemalaria [6,10]. Furthermore, CD4+ T cells
displaying a cytotoxic function are thought to co-express IFN-γ [42,53,54]. To our knowledge,
our study provides the first evidence of a differential IFN-γ production capability and cytotoxic
phenotype betweenCD38+ and CD38- circulating CD4+ T cells in humans, and of a disassocia-
tion between cytotoxicity and IFN-γ production.
Additionally, this CD38+ CD4+ T cell population had a limited ability to produce other pro
and anti-inflammatory cytokines including TNF, IL-2, IL-4, IL-10 and IL-17. This reduced
capacity of CD38+ CD4+ T cells to produce cytokines does not appear to be due to exhaustion
or a form of activation induced cell death since these cells could be activated following TCR
stimulation and were negative for Annexin-V. Thus, CD38+ CD4+ T cells display a phenotype
of functionally active T cells with reduced capacity to produce cytokines, notably IFN-γ. These
observations, together with previous studies on regulatory T cells that identified a positive asso-
ciation betweenCD38 expression on CD4+ T cells and immune suppressive activity [55,56],
further support our hypothesis that CD38+ CD4+ T cells might have a repressive regulatory
function rather than a direct cytotoxic activity against malaria parasites or infected cells.
The CD38+ CD4+ T cells displayed low basal levels of pSTAT1, which is a key transcription
factor associated with IFN-γ signaling [45,57], suggesting that their reduced IFN-γ production
might be associated with a defect in STAT1-signalling pathway. We found that the marked
reduction in basal levels of phosphorylated STAT1 in CD38+ CD4+ T cells is not due to a defect
in responsiveness to IFN-α or to a capability to phosphorylate STAT1, nor could the differ-
ences be accounted for in basal levels of total STAT1 protein. Thus, constitutively lower levels
of activated STAT1 within this cell population might explain the reduced expression of acti-
vated STAT1 measured ex vivowithin CD38+ CD4+ T cells. Alternatively, the difference in
pSTAT1 basal levels betweenCD38+ and CD38- CD4+ T cells might be due to differences in
cytokine responsiveness other than type I or type II IFNs. Indeed, STAT1 can also be phos-
phorylated through IL-6, IL-10 and IL-21 [58]. A more comprehensive cytokine signaling pro-
filing and STAT responsiveness of CD38+ CD4+ T cells in comparison to other CD4+ T cell
subsets could address this question.
CD38+ CD4+ T cells retained their cytotoxic function and impaired ability to produce cyto-
kines throughout infection. Although infection led to significant changes in the phenotype of
both CD38+ and CD38- CD4+ T cell subsets during infection, there was a marked increase in
CD45RA expression and decrease in Ki67 expression within CD38+ but not CD38- CD4+ T
cells. Hence, we speculate that, upon infection, ‘naïve-like’ CD38+ CD4+ T cells proliferate and
differentiate into parasite-specific effectormemory CD4+ T cells, which are then recruited out
of the peripheral blood and into lymphoid organs such as the spleen where they specifically
exert their cytotoxic function. Consistent with this is our observation that there were no
changes in the cytotoxic phenotype of circulating CD38+ CD4+ T cells were observed in the
volunteers following infection.
Both the absolute numbers of CD38+ in CD4+ T cells and relative frequency of CD38+ ver-
sus CD38- CD4+ T cell were increased upon infection. Thus, the accumulation of CD38+ CD4+
T cells in the peripheral blood upon infection is not due to the recruitment of CD38- CD4+ T
cell subsets into other body compartments such as lymphoid organs. Increases in frequency of
CD38+ CD4+ T cells can originate from the activation of circulating CD38- CD4+ T cells
already present in the peripheral blood prior to infection, as suggested in Fig 7. Alternatively,
newly generated CD38+ CD4+ T cells might be originating from other lymphoid organs such
as the spleen and found in the peripheral blood as a ‘spillover’ effect.We found that the
Cytotoxic CD38+ CD4+ T Cells with Impaired IFN-γ
PLOSPathogens | DOI:10.1371/journal.ppat.1005839 September 23, 2016 14 / 22
proportion of CD45RA+ within CD38+ but not CD38- CD4+ T cells is significantly increased
upon infection (Fig 2C) and CD38 has been shown to be preferentially expressed by CD45RA+
CD4+ T cells and might play a role for lymphocyte homing on those cells [33]. Thus CD38+
and CD38- CD4+ T cells might have differential homing properties, so distinct abilities to
migrate between lymphoid organs.
In contrast to CD38+ CD4+ T cells that expanded in experimentally infected volunteers,
the in vitro generated CD38+ CD4+ T cells were fully capable of producing IFN-γ and other
cytokines in response to stimulation. Thus, the reduced ability of CD38+ CD4+ T cells to pro-
duce IFN-γ is a unique feature of CD38+ cells that arise in vivo. Cytokine production by T
cells is highly modulated during T cell differentiation, notably through epigenetic modifica-
tions [59–61]. Thus, it is possible that in vivo the upregulation of CD38 by CD4+ T cells is
accompanied by epigenetic changes that inhibit the transcription of genes coding for cyto-
kines. Thus, we speculate that the analysis of epigenetic modifications to cytokine promoters
in circulating CD38+ CD4+ T cells in the context of natural or experimental infection
will inform the molecularmechanisms controlling cytokine production within this cell
population.
Although an increase in frequency of circulating CD38+ CD4+ T cells has been observed
following immunization or infection in a number of host-pathogen systems [20,23,62], the
role of those cells has not been elucidated, and impaired cytokine capacity has not been
reported. All volunteers in our CHMI study had a pre-existing proportion of CD4+ T cells
expressing CD38 prior to infection, as do all healthy volunteers we have since examined. All
CD38+ CD4+ T cells isolated from healthy volunteers either prior to infection, or during
experimentalmalaria infection, displayed similar features clearly distinguishing them from
CD38- CD4+ T cells. Taken together, these results lead us to speculate that this cell population
might also expand during other infections. This could explain the variation observed in the
pre-existing proportion of CD38+ cells among total CD4+ T cells between individuals (ranging
from 0.9 to 10.9% of total CD4+ T cells), reflecting a more or less recent infection with a path-
ogen. This idea is also supported by the recent study from Tsang et al, which highlighted that
the proportion of CD4+ T cells expressing CD38 was a feature presenting very high inter-indi-
vidual variability [63].
In conclusion, we have identified a unique population of circulating CD38+ CD4+ T cells in
humans with characteristics that clearly distinguish them from other CD4+ T cells; specifically,
markers of recent activation and cytotoxic potential but impaired cytokine production. This
CD4+ T cell population was specifically expanded in experimental blood-stagemalaria infec-
tion and was significantly associated with reduced parasite burden. This is consistent with a
critical role for these cells in protective immunity to malaria. Further insights into the function
and origin of this cell population might provide novel immune correlates of protection in
blood-stagemalaria and other infectious diseases, and inform vaccine design.
Material andMethods
Ethics statement
Experimental infection of malaria-naive healthy adult volunteers was undertaken at QPharm
Pty Ltd (Brisbane, Australia) with approval of the QIMR BerghoferMedical Research Institute
Human Research Ethics Committee (QIMRB-HREC) and Medicines for Malaria Venture
(MMV). Clinical studies were registered on the Australian and New ZealandClinical Trials Reg-
istry (ANZCTR): clinical trial numbers ACTRN12612000814875, ACTRN12613000565741 and
ACTRN12613001040752. All subjects were enrolled with written informed consent.
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Samples fromP. falciparumexperimentally infected volunteers
Inoculum preparation, volunteer recruitment, infection,monitoring and treatment were per-
formed as describedpreviously [64]. In brief, healthy malaria-naive individuals were intrave-
nously inoculatedwith 1,800 viable P. falciparum parasitized erythrocytes, and treated with
anti-malarial drugs at seven to eight days post-infection.Blood samples were collected prior
to infection and seven days post-infection (before anti-malarial drug treatment). Peripheral
blood from healthy volunteers was also collected under informed consent and approval by the
QIMRB-HREC. Peripheral blood collected in LithiumHeparin Vacutainers (BD Biosciences)
was either used directly for flow cytometry analysis, or peripheral bloodmononuclear cells
(PBMC) isolated using standard Ficoll density gradient centrifugation.
Determinationof parasite burden in P. falciparumexperimentally
infected volunteers
Parasitemia levels over the course of the infectionwere determined using a consensus P. falcip-
arum species-specificquantitative PCR assay from 500 μl of packed red blood cells as previ-
ously described [65]. Parasite levels were assessed once daily until day four post-infection and
then twice daily until treatment. All samples were batch tested in triplicate together after each
study completion. The total parasite burden across the first seven days of infectionwas defined
as the area under the curve of the transformed parasite levels from day 0 to day 7 of infection
using the trapezoidal rule. The limit of detectionwas 64 parasites/500 μl packed red blood cells
[65].
Flow cytometryantibodies and staining buffer
Details about the clones, manufacturers and optimum dilutions for each antibody used in this
study are listed in S1 Table. Unless otherwise stated, staining buffer was a PBS solution supple-
mented with 0.5% FCS and 4 mM EDTA and filtered through 0.2 μm.
Flow cytometric analysis fromwhole blood
Whole blood collected in LithiumHeparin vacutainers was lysed and fixed with BD FACS lys-
ing solution (BD Biosciences) and lymphocytes permeabilizedwith BD FACS permeabilizing
solution 2 (BD Biosciences) according to the manufacturer’s instructions. Cells were then
resuspended in 50 μl of staining buffer containing surface and intracellular antibodies at previ-
ously determined optimum dilution along with 1 μl of human Fc receptor blocking solution
(Human TruStain FcX, Biolegend) for 30 mins at room temperature, washed and resuspended
in staining buffer. Samples were acquired using a LSR Fortessa 4 (BD Biosciences) with Diva
software, and analyzed using FlowJo software (version 6.0).
Flow cytometric analysis fromPBMC and sortedCD4+ T cells
Approximately 5x105 cells were washed in PBS, resuspended in 100 μl PBS containing 0.1 μl
Zombie Yellow fixable viability dye (Biolegend) and incubated for 15 mins at 4°C. Cells were
then washed, resuspended in 20 μl of staining buffer containing surface antibodies at previously
determined optimum dilution along with 1 μl of human Fc receptor blocking solution for 20
mins at 4°C, fixed in 50 μl of 1% paraformaldehyde solution for 15 mins at room temperature,
washed, resuspended in 15 μl of BD Perm/Wash buffer 1x (BD Biosciences) containing intra-
cellular antibodies at previously determined optimum dilution for 30 mins at 4°C, washed with
BD Perm/Wash 1x solution, and resuspended in staining buffer. Samples were acquired using
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a LSR Fortessa 4 (BD Biosciences) with Diva software, and analyzed using FlowJo software
(version 6.0).
Phosphoflow on whole blood
200 μl of whole bloodwas stained with anti-human CD4-BV510, anti-human CD8-APC-H7
and anti-human CD38-APC at previously determined optimum dilution for 15 mins at 37°C
with or without recombinant human IFN-α2 (Biolegend) or recombinant human IFN-γ (Pro-
Spec) at 100 ng/mL.Whole bloodwas lysed and fixed with Phosflow Lyse/fix 1x solution (BD
Biosciences) and lymphocytes permeabilizedwith BD Perm III solution (BD Biosciences)
according to the manufacturer’s instructions. Cells were then resuspended in 50 μl of staining
buffer containing anti-human pSTAT1-PECF594, anti-human pSTAT4-AF488 and anti-
human pSTAT5-PE at previously determined optimum dilution for one hour at room temper-
ature. Cells were washed and resuspended in staining buffer. Samples were acquired using a
LSR Fortessa 4 (BD Biosciences) with Diva software, and analyzed using FlowJo software (ver-
sion 6.0).
Cell sorting
CD38+ and CD38- CD4+ T cells were sorted from freshly isolated or cryopreservedPBMC.
Approximately 20x106 PBMC were resuspended in 50 μl of staining buffer containing anti-
human CD4-BV510, anti-human CD8-APC-H7 and anti-human CD38-PerCpCy5.5 at previ-
ously determined optimum dilution for 20 mins at 4°C, washed and resuspended in staining
buffer. Just before the sorting, 1 μg/mL of propidium iodide (Sigma-Aldrich) was added to
allow for assessment of viability. Pi-CD4+CD8-CD38+ and Pi-CD4+CD8-CD38- cells were
sorted using a BD Aria III cell sorter (BD Biosciences) directly in staining buffer and kept on
ice until further use for in vitro assays.
Gene expression on ex vivo or in vitro stimulated sorted cells
RNA was extracted from sorted CD38+ and CD38- CD4+ T cells directly ex vivo by resuspend-
ing the cells directly in RLT buffer or after in vitro stimulation to induce cytokine production.
For the in vitro stimulation assay, sorted cells were plated at 50,000 cells/well in RPMI 1640
containing 25 mMHepes, 2 mM L-glutamine (Invitrogen), and supplemented with 10 units/
mL of Penicillin (Life Technologies), 10 μg/mL of Streptomycin (Life Technologies) and 10%
fetal bovine serum (Life Technologies) and stimulated with 5 ng/mL of phorbol myristate ace-
tate PMA (Sigma Aldrich) and 500 ng/mL Ionomycin (Sigma Aldrich) for 5h at 37°C in an
atmosphere of 5% C02. Following stimulation, supernatants were harvested, cell pellets resus-
pended in RLT buffer and stored at -70°C. On the day of extraction, frozen cell lysates were
thawed quickly on ice and mRNA was extracted using the RNEasymicro kit (Qiagen) accord-
ing to the manufacturer’s instructions. cDNA was synthesized using oligo-dT and Superscript
III RT (Invitrogen) according to the manufacturer’s instructions. Eomes, Granzyme B, Gran-
zyme A, Granzyme K, IFN-γ, IL-2, IL-4, IL-10, IL-17A, Perforin, RPL13A, and TNF gene
expression were measured from 1 μl of cDNA (or pre-amplified cDNA) using individual Taq-
man gene expression assays (Life Technologies) and Platinum Taq polymerase (Life technolo-
gies) in a 10 μl volume reaction on a 384-well plate using the Light Cycler 480 real time PCR
cycler (Roche) according to the manufacturer’s instructions. Each gene expression was assayed
in duplicate. Cycling conditions used were: 50°C for 2 mins followed by 95°C for 10 mins, 40
cycles at 95°C for 15 secs and 60°C for 1 min. Fold changes were calculatedwith the ddCt value
method [66] using RPL13A expression as the reference gene, and the expression values from
the unstimulated cells as baseline.
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Intracellular cytokine staining on sortedcells
SortedCD38+ and CD38- CD4+ T cells were plated at 50,000 cells/well in RPMI 1640 contain-
ing 25 mMHepes, 2 mM L-glutamine, supplemented with 10 units/mL of Penicillin, 10 μg/mL
of Streptomycin and 10% fetal bovine serum and stimulated with 5 ng/mL of phorbol myristate
acetate and 500 ng/mL Ionomycin for 5h at 37°C in an atmosphere of 5% C02. After one hour,
Brefeldin A (GolgiPlug, BD Biosciences) was added at 1 μg/ml. Following stimulation, cells
were washed, resuspended in 20 μl of staining buffer containing anti-human CD4-BV510 and
anti-human CD8-APC-H7 at previously determined optimum dilution for 20 mins at 4°C,
fixed in 50 μl of 1% paraformaldehyde solution for 15 mins at room temperature, washed,
resuspended in 15 μl of BD Perm/Wash buffer 1x (BD Biosciences) containing anti-human
IFN-γ-FITC at previously determined optimum dilution for 30 mins at 4°C, washed with BD
Perm/Wash 1x solution, and resuspended in staining buffer before acquisition on LSR Fortessa
4 (BD Biosciences) with Diva software. FlowJo version 6.0 was used for gating.
TCR stimulation assay on sortedcells
SortedCD38+ and CD38- CD4+ T cells were plated at 50,000 cells/well in RPMI 1640 contain-
ing 25 mMHepes, 2 mM L-glutamine, and supplemented with 10 units/mL of Penicillin,
10 μg/mL of Streptomycin and 10% fetal bovine serum in a 96-well plate pre-coated overnight
with 10 μg/mL of anti-human CD3 OKT3 antibody (Biolegend) and incubated for 5 h at
37°C in an atmosphere of 5% C02. Following stimulation, cells were resuspended in 20 μl of
staining buffer containing anti-human CD4-BV510, anti-human CD8-APC-H7, anti-human
CD69-AF700 at previously determined optimum dilution for 20 mins at 4°C, washed and
resuspended in staining buffer before acquisition on LSR Fortessa 4 (BD Biosciences) with
Diva software. FlowJo version 6.0 was used for gating.
In vitro generation of CD38+ CD4+ T cells
SortedCD38- CD4+ T cells from healthy uninfected volunteers were plated at 0.5x106 cells/well
in RPMI 1640 containing 25 mMHepes, 2 mM L-glutamine, supplemented with 10 units/mL
of Penicillin, 10 μg/mL of Streptomycin and 5% human AB serum (Sigma Aldrich) and stimu-
lated with P. falciparum parasitized red blood cells extract at 1x106 pRBC/ml or PHA at 5 μg/
mL (Sigma Aldrich) for six days at 37°C in an atmosphere of 5% C02. Following stimulation,
cells were either used directly for flow cytometric analysis, or further sorted into CD38+ and
CD38- cells for in vitro stimulation and gene expression analysis as described above.
Statistical analysis
Statistical analyses were performed using GraphPad Prism Software (version 6). Normality was
assessed using D’Agostino and Pearson Omnibus normality test and showed the datasets were
not normally distributed. Therefore, all paired datasets were compared using the non-paramet-
ricWilcoxon test. All univariate and multivariate analysis were performedwith R. Univariate
analysis was performedwith a linear regression analysis and p values were adjusted for multiple
comparisons using the Bonferroni method.Multivariate analysis was performedwith a multi-
variate linear regression analysis with forward stepwise covariate selection using Akaike infor-
mation criteria. P values less than 0.05 were considered as significant.
Supporting Information
S1 Table. Antibodies used for flow cytometry.
(DOCX)
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S1 Fig. Absolute CD69+ and CD38+ T cell counts during P. falciparumexperimental
blood-stage infection. Peripheral bloodwas collected prior to and seven days post-infection.
Absolute lymphocyte counts were determined by full blood count and the frequency of CD69+
or CD38+ T cells and B cells determined by flow cytometry. Graph show combined data from
22 volunteers from five independent cohorts; statistical differences between pre- and post-
infectionwere determined using the non-parametricWilcoxon test; box and whisker plots
indicate median, interquartile range and min-max; ns, p> 0.05.
(TIF)
S2 Fig. Absolute CD4+ T cell counts during P. falciparum experimental blood-stage infec-
tion. Peripheral bloodwas collected prior to and seven days post-infection.Absolute lympho-
cyte counts were determined by full blood count and the frequency of CD4+ T cells amongst
lymphocytes determined by flow cytometry. Graph show combined data from 22 volunteers
from five independent cohorts; statistical differences between pre- and post-infectionwere
determined using the non-parametricWilcoxon test; box and whisker plots indicate median,
interquartile range and min-max; ns, p> 0.05.
(TIF)
S3 Fig. Cytokine production by in vitro generated CD38+ CD4+ T cells from CD38- CD4+ T
cells.CD38+ CD4+ T cells were generated in vitro from CD38- CD4+ T cells isolated from
peripheral blood of healthy volunteers by in vitro stimulation with P. falciparum parasitized
red blood cells extract (pRBC) at 106 pRBC/mL for 6 days. Their cytokine gene expression was
measured by RT-qPCR after brief mitogenic stimulation with PMA and Ionomycin. Gene
expression was normalized to reference gene RPL13A. Graphs show combined data from four
volunteers. Box and whisker plots indicate median, interquartile range and min-max.
(TIF)
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